CN117203206A - Gcn2调节化合物及其用途 - Google Patents

Gcn2调节化合物及其用途 Download PDF

Info

Publication number
CN117203206A
CN117203206A CN202280022926.3A CN202280022926A CN117203206A CN 117203206 A CN117203206 A CN 117203206A CN 202280022926 A CN202280022926 A CN 202280022926A CN 117203206 A CN117203206 A CN 117203206A
Authority
CN
China
Prior art keywords
alkyl
membered
cancer
halogen
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022926.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·拉穆尔蒂
M·J·穆尔维希尔
B·谢伯恩
B·拉希姆图拉
E·P·A·塔尔博特
C·G·汤姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebsel Co ltd
Original Assignee
Hebsel Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebsel Co ltd filed Critical Hebsel Co ltd
Publication of CN117203206A publication Critical patent/CN117203206A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Holo Graphy (AREA)
CN202280022926.3A 2021-01-22 2022-01-21 Gcn2调节化合物及其用途 Pending CN117203206A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163140314P 2021-01-22 2021-01-22
US63/140,314 2021-01-22
PCT/US2022/013383 WO2022159746A1 (en) 2021-01-22 2022-01-21 Gcn2 modulating compounds and uses thereof

Publications (1)

Publication Number Publication Date
CN117203206A true CN117203206A (zh) 2023-12-08

Family

ID=80446635

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022926.3A Pending CN117203206A (zh) 2021-01-22 2022-01-21 Gcn2调节化合物及其用途

Country Status (14)

Country Link
US (1) US20240083897A1 (cg-RX-API-DMAC10.html)
EP (1) EP4281182A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024504364A (cg-RX-API-DMAC10.html)
KR (1) KR20240021143A (cg-RX-API-DMAC10.html)
CN (1) CN117203206A (cg-RX-API-DMAC10.html)
AU (1) AU2022210760A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023014723A2 (cg-RX-API-DMAC10.html)
CA (1) CA3209124A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023010940A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230408A (cg-RX-API-DMAC10.html)
IL (1) IL304611A (cg-RX-API-DMAC10.html)
MX (1) MX2023008589A (cg-RX-API-DMAC10.html)
PE (1) PE20240691A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022159746A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
KR20250017238A (ko) * 2022-05-25 2025-02-04 히버셀, 인크. 암을 치료하기 위한 gcn2 조정제
WO2024077092A1 (en) * 2022-10-04 2024-04-11 Hibercell, Inc. Gcn2 inhibitor for treating metastases
EP4652170A1 (en) * 2023-01-20 2025-11-26 Hibercell, Inc. Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3- sulfonamido)-2,6-difluorophenyl)-n-methylimidazo[l,5- ajpyrazine-l-carboxamide and methods for using the same
IL328829A (en) * 2023-12-08 2026-08-01 Hibercell Inc Methods for treating acute myeloid leukemia using combinations of GCN2 modulators, ventocalx and azaraglitidine
WO2025137710A1 (en) * 2023-12-22 2025-06-26 Hibercell, Inc. Methods of treating cancer using combinations of gcn2 modulators and belzutifan

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863774A (zh) * 2003-10-08 2006-11-15 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
US20110257165A1 (en) * 2008-12-19 2011-10-20 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
US20190169166A1 (en) * 2016-08-10 2019-06-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2020210828A1 (en) * 2019-04-12 2020-10-15 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3089762A1 (en) * 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
EP4107146A1 (en) * 2020-02-17 2022-12-28 Alesta Therapeutics BV Gcn2 modulator compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863774A (zh) * 2003-10-08 2006-11-15 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
US20110257165A1 (en) * 2008-12-19 2011-10-20 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
US20190169166A1 (en) * 2016-08-10 2019-06-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2020210828A1 (en) * 2019-04-12 2020-10-15 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions

Also Published As

Publication number Publication date
WO2022159746A1 (en) 2022-07-28
AU2022210760A1 (en) 2023-09-07
US20240083897A1 (en) 2024-03-14
PE20240691A1 (es) 2024-04-10
CR20230408A (es) 2024-05-07
EP4281182A1 (en) 2023-11-29
BR112023014723A2 (pt) 2023-10-03
KR20240021143A (ko) 2024-02-16
CO2023010940A2 (es) 2023-12-11
MX2023008589A (es) 2023-08-09
JP2024504364A (ja) 2024-01-31
CA3209124A1 (en) 2022-07-28
IL304611A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
US11390584B2 (en) 1-cyano-pyrrolidine compounds as USP30 inhibitors
AU2018270685C1 (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
AU2020348675B2 (en) Azole-fused pyridazin-3(2H)-one derivatives
CN103492384B (zh) 作为trk抑制剂的化合物和组合物
AU2022210760A1 (en) Gcn2 modulating compounds and uses thereof
CN108602776A (zh) 用作irak抑制剂的杂芳基化合物及其用途
EP3562809B1 (en) Pyrazolopyrimidine compounds and methods of use thereof
US20170305857A1 (en) N-acylpiperidine ether tropomyosin-related kinase inhibitors
CN115335057A (zh) 抑制酪蛋白激酶的方法
CA2885259A1 (en) Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
HK40076219B (en) Azole-fused pyridazin-3(2h)-one derivatives
HK40076219A (en) Azole-fused pyridazin-3(2h)-one derivatives
CN120303269A (zh) 用于调节hur(elavl1)的化合物
HK40043421B (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
JP2023503988A (ja) Ｄｕｘ４発現に関連する疾患を処置するための新たな化合物
HK1262853B (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination